| 76.09 -3.48 (-4.37%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 100.31 | 1-year : | 110.34 |
| Resists | First : | 85.88 | Second : | 94.47 |
| Pivot price | 83.95  |
|||
| Supports | First : | 72 | Second : | 59.9 |
| MAs | MA(5) : | 82.28 |
MA(20) : | 83 |
| MA(100) : | 46.8 |
MA(250) : | 0 | |
| MACD | MACD : | 3.6 |
Signal : | 5.6 |
| %K %D | K(14,3) : | 13.3 |
D(3) : | 27.8 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 94.47 | Low : | 10.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INBX ] has closed above bottom band by 3.3%. Bollinger Bands are 3.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 81.56 - 82.34 | 82.34 - 82.82 |
| Low: | 73.22 - 74.19 | 74.19 - 74.78 |
| Close: | 74.97 - 76.56 | 76.56 - 77.52 |
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Fri, 12 Dec 2025
Mark Asset Management LP Buys Shares of 17,000 Inhibrx Biosciences, Inc. $INBX - MarketBeat
Wed, 10 Dec 2025
Franklin Resources Inc. Makes New $316,000 Investment in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Thu, 04 Dec 2025
Inhibrx Biosciences stock hits all-time high at 87.89 USD By Investing.com - Investing.com Nigeria
Fri, 14 Nov 2025
Inhibrx Reports Third Quarter 2025 Financial Results - PR Newswire
Tue, 04 Nov 2025
Inhibrx Announces Participation in Upcoming Scientific Conferences - PR Newswire
Mon, 27 Oct 2025
Inhibrx Biosciences: Cruising Toward FDA Approval, But Getting Ahead Of Itself - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 7.87e+006 (%) |
| Held by Institutions | 27 (%) |
| Shares Short | 1,030 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9252e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 937.8 % |
| Return on Equity (ttm) | -61 % |
| Qtrly Rev. Growth | 1.4e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -12 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -143 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.32e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|